Cisternas P, Taylor X, Perkins A, Maldonado O, Allman E, Cordova R, Marambio Y, Munoz B, Pennington T, Xiang S, Zhang J, Vidal R, Atwood B, Lasagna-Reeves CA. Vascular amyloid accumulation alters the gabaergic synapse and induces hyperactivity in a model of cerebral amyloid angiopathy.  Aging Cell. 2020 Sep 10:e13233. doi: 10.1111/acel.13233.

Taylor X, Cisternas P, You Y, You Y, Xiang S, Marambio Y, Zhang J, Vidal R, Lasagna-Reeves CA. 

A1 reactive astrocytes and a loss of TREM2 are associated with an early stage of pathology in a mouse model of cerebral amyloid angiopathy. J Neuroinflammation. 2020 Jul 25;17(1):223. doi: 10.1186/s12974-020-01900-7.



Bemiller SM, McCray TJ, Allan K, Formica SV, Xu G, Wilson G, Kokiko-Cochran ON, Crish SD, Lasagna-Reeves CA, Ransohoff RM, Landreth GE, Lamb BT. TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol Neurodegener. 2017 Oct 16;12(1):74.


M.W. Rousseaux, M. De Haro, C.A. Lasagna-Reeves, A. De Maio, J. Park, I, Al-Ramahi, N. Lu, A. Sharma, L. Vilanova-Velez, T.F. Westbrook, J.C. Troncoso, R. Kayed, J. Botas, H.Y. Zoghbi. TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau. Elife 2016 Oct 25;5.

C.A Lasagna-Reeves, M. De Haro, S. Hao, J. Park, M.W.C. Rousseaux, I. Al-Ramahi, P. Jafar-Nejad, L. Vilanova-Velez, L. See, A. De Maio, Z. Wu, J.C. Troncoso, T.F. Westbrook, J. Tang,J. Botas, H.Y. Zoghbi. Reduction of Nuak1 decreases tau and reverses symptoms in a tauopathy mouse model. Neuron 2016 Oct 19;92(2):407-418.

Subject of a Neuron Preview commentary by S. Maeda and L. Mucke., 2016 Oct 19;92(2):265-267.

Subject of a Science Signaling Editors’ Choice by Leslie K. Ferrareli., 2016 Oct 9;45: ec252. Featured at Alzforum


C.A. Lasagna-Reeves, M.W.C. Rousseaux, M.J. Guerrero-Munoz, L. Vilanova-Velez, J. Park, L. See, P. Jafar-Nejad, R.Richaman, H.T. Orr, R. Kayed and H.Y. Zoghbi. ATAXIN-1 oligomers induce local spread of pathology and decreasing them by passive immunization slowls Spinocerebellar ataxia type 1 phenotypes. Elife 2015 December 17;4

C.A. Lasagna-Reeves, M.W.C. Rousseaux, M.J. Guerrero-Munoz, J. Park, R.Richaman, N. Lu, U. Sengupta, A. Litvinchuk, H.T. Orr, R. Kayed and H.Y. Zoghbi. A native interactor scaffolds and stabilizes toxic ATXIN-1 oligomers in SCA1. Elife. 2015 May 19;4.

Sengupta, M.J. Guerrero-Munoz, D. L. Castillo-Carranza, C.A. Lasagna-Reeves, J.E. Gerson, G.R. Jackson and R. Kayed. Synergistic toxicity of oligomeric α-synuclein and tau in synucleinopathies. Biol Psychiatry. 2015 Jan 9.

Subject of a Biological Psychiatric editorial commentary by Delenclos, M. Moussaud, S. and McLean, P.J., 2015 Nov 15;78(10):666-7.


C.A. Lasagna-Reeves, D.L. Castillo-Carranza, U. Sengupta, J.E. Gerson, M.J. Guerrero-Munoz, J.C. Troncoso, G.R. Jackson and R. Kayed. The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotype. Acta Neuropathol Commun. 2014 May 29;2:56.

D.L. Castillo-Carranza, U. Sengupta, M.J. Guerrero-Munoz, C.A. Lasagna-Reeves, J.E. Gerson, G. Singh, D.M. Estes, A.D. Barrett, K.T. Dineley, J.R. Jackson and R. Kayed. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci. 2014 Mar 19;34(12):4260-72.

M.J. Guerrero-Munoz, D. L. Castillo-Carranza, S. Krishnamurthy, A. Paulucci-Holthauzen, U. Sengupta, C.A. Lasagna-Reeves, G.R. Jackson and R. Kayed. Amyloid-β oligomers as a template for secondary amyloidosis in Alzheimer’s disease. Neurobiol Dis. 2014 Nov 71:14-23.

J.E. Gerson, U. Sengupta, C.A. Lasagna-Reeves, M.J. Guerrero-Munoz, J.C. Troncoso and R. Kayed. Characterization of tau oligomeric seeds in Progressive Supranuclear Palsy. Acta Neuropathol Commun. 2014 Jun 14;2:73.

D.L. Castillo-Carranza, J.E. Gerson, U. Sengupta, M.J. Guerrero-Munoz, C.A. Lasagna-Reeves and R. Kayed. Specific Targeting of Tau Oligomers in Htau Mice Prevents Cognitive Impairment and Tau Toxicity Following Injection with Brain-Derived Tau Oligomeric Seeds. J Alzheimer’s Dis. 2014 Mar 6;40 Suppl 1: S97-S111.


Kayed and C.A. Lasagna-Reeves. Molecular Mechanism of Amyloid Oligomers Toxicity, J Alzheimer’s Dis. 2013 Jan 1;33(0):S67-78.

D.L. Castillo-Carranza, C.A. Lasagna-Reeves, R. Kayed. Tau aggregates as immunotherapeutic targets. Front Biosci (Schol Ed). 2013 Jan 1;5:426-38.

C.A. Lasagna-Reeves, A.L. Clos, D. Castillo-Carranza, U. Sengupta, M. Guerrero-Muñoz , B. Kelly, R. Wagner, R. Kayed. Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity, Biochem Biophys Res Commun. 2013 Jan 18;430(3):963-8.


C.A. Lasagna-Reeves, D.L. Castillo-Carranza,  U. Sengupta, M.J. Guerrero-Munoz, T. Kiritoshi, V. Neugebauer, G.R. Jackson, R. Kayed. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau, Sci Rep. 2012;2:700.

C.A. Lasagna-Reeves, D. L. Castillo-Carranza, U. Sengupta, J. Sarmiento, J. Troncoso, G.R. Jackson and R. Kayed. Identification of oligomers at early stages of tau aggregation in Alzheimer’s disease, FASEB J, 2012 May;26(5):1946-59.

A.L. Clos, R. Kayed and C.A. Lasagna-Reeves. Association of skin with the pathogenesis and treatment of neurodegenerative amyloidosis. Front Neurol, 2012;3:5.


C.A. Lasagna-Reeves and R. Kayed. Astrocytes contain amyloid-β annular protofibrils in Alzheimer’s disease brains. FEBS Lett, 2011 Oct 3;585(19):3052-7.

A.L. Clos, C.A. Lasagna-Reeves, D. L. Castillo-Carranza, U. Sengupta, G.R. Jackson, B. Kelly, Thomas M. Beachkofsky and R. Kayed. Formation of immunoglobulin light chain amyloid oligomers in primary cutaneous nodular amyloidosis. Br J Dermatol, 2011 Dec;165(6):1349-54.

 A.L. Clos, C.A. Lasagna-Reeves, B. Kelly, R. Wagner, M. Wilkerson, G.R. Jackson and R. Kayed. Role of oligomers in the amyloidogenesis of cutaneous amyloidosis. J Am Acad Dermatol, 011 Nov;65(5):1023-31.

 C.A. Lasagna-Reeves, D. Castillo-Carranza, U. Sengupta, A.L. Clos, G.R. Jackson and R. Kayed. Tau oligomers impair memory and induce synaptic and mitocondrial dysfunction in wild type mice. Mol Neurodegener, 2011 Jun 6; 6(1):39. (Most accessed research article in the first 30 days of its publication).

C.A. Lasagna-Reeves, D. Castillo-Carranza, G.R. Jackson and R. Kayed. Tau oligomers as Potential target for immunotherapy for Alzheimer’s disease and tauopathies. Current Alzheimer Res, 2011 Sep 1;8(6):659-65.

C.A. Lasagna-Reeves, C. Glabe and R. Kayed. Amyloid- annular protofibrils evade fibrillar fate in Alzheimers disease brain. J Biol Chem, 2011 Jun 24;286(25):22122-30. (Selected as Paper of the week, top 1% of papers published in J Biol Chem).


C.A. Lasagna-Reeves, D. Castillo-Carranza, M. Guerrero-Muñoz, G.R. Jackson and R.Kayed. Preparation and Characterization of Neurotoxic Tau Oligomers. Biochemistry, 2010 Nov; 49(47):10039-10041. (Most accessed research article in the first 30 days of its publication)

 C.A. Lasagna-Reeves, A.L. Clos, T. Midoro-Horiuti, R. Goldblum, G. R. Jackson and R. Kayed.  Inhaled insulin forms toxic pulmonary amyloid aggregates. Endocrinology, 2010 Oct; 151(10):4717-24.

 A. L. Clos, C. Lasagna-Reeves, R. Wagner, B. Kelly, G.R. Jackson and R. Kayed. Therapeutic removal of amyloid deposits in cutaneous amyloidosis by localized intra-lesional injections of anti-amyloid antibodies. Exp. Dermatology, 2010 Oct;19(10):904-11

C. Lasagna-Reeves, D. González-Romero, M. Barria, I. Olmedo, A.L. Clos, V.M. Sadagopa Ramanujam, A. Urayama, L. Vergara, M.J. Kogan and C. Soto. Bioaccumulation and toxicity of gold nanoparticles after repeated administration in Mice. Biochem. Biophys. Res. Commun. 2010 Mar 19; 393(4):649-55. (Top five most cited articles in BBRC since 2009).


E.W. Mina, C. Lasagna-Reeves, C.G. Glabe and R. Kayed. Polaxamer 188 copolymer membrane sealant rescues toxicity of amyloid oligomers in vitro. Journal of Molecular Biology, 2009, Aug 21; 391(3):577-85.


Z. Martin-Jones and C. Lasagna-Reeves. Which is a better target for AD immunotherapy Aβ or Tau? Review.  Alzheimer Dis Assoc Disord, 2008. 22 (2): 111-2.